REPORT ID 5109

United States Neurotherapeutic Drugs Market Report 2017

Publish Date
20-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the United States Neurotherapeutic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Neurotherapeutic Drugs in these regions, from 2012 to 2022 (forecast).

United States Neurotherapeutic Drugs market competition by top manufacturers/players, with Neurotherapeutic Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Abbott
    BD
    Novartis AG
    Johnson & Johnson
    Pfizer
    Sanofi-Aventis
    Biogen
    GlaxoSmithKline
    AstraZeneca
    Merck

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Peripheral Nervous System Disorders (PNS) Disorder
    Autonomous Nervous System (ANS) Disorder
    Central Nervous System (CNS) Disorders
    Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hosptical
    Drug Stores
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Neurotherapeutic Drugs Market Report 2017
1 Neurotherapeutic Drugs Overview
    1.1 Product Overview and Scope of Neurotherapeutic Drugs
    1.2 Classification of Neurotherapeutic Drugs by Product Category
        1.2.1 United States Neurotherapeutic Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Neurotherapeutic Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Peripheral Nervous System Disorders (PNS) Disorder
        1.2.4 Autonomous Nervous System (ANS) Disorder
        1.2.5 Central Nervous System (CNS) Disorders
        1.2.6 Other
    1.3 United States Neurotherapeutic Drugs Market by Application/End Users
        1.3.1 United States Neurotherapeutic Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hosptical
        1.3.3 Drug Stores
        1.3.4 Other
    1.4 United States Neurotherapeutic Drugs Market by Region
        1.4.1 United States Neurotherapeutic Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Neurotherapeutic Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Neurotherapeutic Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Neurotherapeutic Drugs Status and Prospect (2012-2022)
        1.4.5 New England Neurotherapeutic Drugs Status and Prospect (2012-2022)
        1.4.6 The South Neurotherapeutic Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Neurotherapeutic Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Neurotherapeutic Drugs (2012-2022)
        1.5.1 United States Neurotherapeutic Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Neurotherapeutic Drugs Revenue and Growth Rate (2012-2022)

2 United States Neurotherapeutic Drugs Market Competition by Players/Suppliers
    2.1 United States Neurotherapeutic Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Neurotherapeutic Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Neurotherapeutic Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Neurotherapeutic Drugs Market Competitive Situation and Trends
        2.4.1 United States Neurotherapeutic Drugs Market Concentration Rate
        2.4.2 United States Neurotherapeutic Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Neurotherapeutic Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Neurotherapeutic Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Neurotherapeutic Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Neurotherapeutic Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Neurotherapeutic Drugs Price by Region (2012-2017)

4 United States Neurotherapeutic Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Neurotherapeutic Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Neurotherapeutic Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Neurotherapeutic Drugs Price by Type (2012-2017)
    4.4 United States Neurotherapeutic Drugs Sales Growth Rate by Type (2012-2017)

5 United States Neurotherapeutic Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Neurotherapeutic Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Neurotherapeutic Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Neurotherapeutic Drugs Players/Suppliers Profiles and Sales Data
    6.1 Abbott
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Abbott Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 BD
        6.2.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 BD Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Johnson & Johnson
        6.4.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Johnson & Johnson Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Pfizer
        6.5.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Pfizer Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Sanofi-Aventis
        6.6.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Sanofi-Aventis Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Biogen
        6.7.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biogen Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 GlaxoSmithKline
        6.8.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 GlaxoSmithKline Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 AstraZeneca
        6.9.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 AstraZeneca Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Merck
        6.10.2 Neurotherapeutic Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Merck Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Neurotherapeutic Drugs Manufacturing Cost Analysis
    7.1 Neurotherapeutic Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Neurotherapeutic Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Neurotherapeutic Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Neurotherapeutic Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Neurotherapeutic Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Neurotherapeutic Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Neurotherapeutic Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Neurotherapeutic Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Neurotherapeutic Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer